Results 111 to 120 of about 220,141 (335)

Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Most antiseizure medications (ASMs) are prescribed off label for neonates. Lacosamide's efficacy in infants and availability in intravenous formulation suggest potential utility for neonates. We evaluated the safety and efficacy of lacosamide for neonatal seizures. Methods This 10‐center, retrospective study of neonates with seizures
Alexandra Santana Almansa   +15 more
wiley   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker   +20 more
wiley   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa   +2 more
wiley   +1 more source

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor   +3 more
wiley   +1 more source

Cyclical Neutropenia [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1968
D I, Evans, A, Holzel
openaire   +2 more sources

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

open access: yesInternational Journal of Cancer, EarlyView.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea   +5 more
wiley   +1 more source

Neutropenias congénitas Congenital neutropenias

open access: yesRevista Cubana de Hematología, Inmunología y Hemoterapia, 2004
Los neutrófilos desempeñan un papel vital en la protección del organismo frente a infecciones bacterianas y micóticas. La neutropenia crónica severa, se define como un número absoluto de neutrófilos menor de 500xmm3 que persiste meses o años. Las causas de esta condición son múltiples; pueden ser congénitas y existir desde el nacimiento, o adquiridas y
Aramís Núñez Quintana   +3 more
openaire   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy